Regulation of the gp80 and gp130 subunits of the IL-6 receptor by sex steroids in the murine bone marrow

Journal of Clinical Investigation

Volumn 100, Issue 8, 1997, Pages 1980-1990

  Lin, Song Chang ^c   Yamate, Tomoo ^c   Taguchi, Yasuto ^c   Borba, Victoria Z C ^c   Girasole, Giuseppe ^b   O'Brien, Charles A ^c   Bellido, Teresita ^c   Abe, Etsuko ^c   Manolagas, Stavros C ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF PARMA   (Italy)

^c NONE

Author keywords

Androgen; Cytokine receptors; Cytokines; Estrogen; Osteoporosis

Indexed keywords

ANDROGEN; ESTROGEN; INTERLEUKIN 6 RECEPTOR; SEX HORMONE; VIRUS GLYCOPROTEIN;

ANIMAL TISSUE; ARTICLE; BONE MARROW; CONTROLLED STUDY; HYPERPARATHYROIDISM; MOUSE; NONHUMAN; OSTEOLYSIS; OSTEOPOROSIS; OVARIECTOMY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION;

EID: 0030770949     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI119729     Document Type: Article

References (64)

1. Manolagas, S.C., and R.L. Jilka. 1995. Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N. Engl. J. Med. 332:305-311.
2. Jilka, R.L., G. Hangoc, G. Girasole, G. Passeri, D.C. Williams, J.S. Abrams, B. Boyce, H. Broxmeyer, and S.C. Manolagas. 1992. Increased osteoclast development after estrogen loss: Mediation by interleukin-6. Science (Wash. DC). 257:88-91.
3. Bellido, T., R.L. Jilka, B.F. Boyce, G. Girasole, H. Broxmeyer, S.A. Dalrymple, R. Murray, and S.C. Manolagas. 1995. Regulation of interleukin-6, osteoclastogenesis and bone mass by androgens. The role of the androgen receptor. J. Clin. Invest. 95:2886-2895.
4. Manolagas, S.C., R.L. Jilka, T. Bellido, C.A. O'Brien, and A.M. Parfitt. 1996. Interleukin-6 type cytokines and their receptors. In Principles of Bone Biology. J.P. Bilezikian, L.G. Raisz, and G.A. Rodan, editors. Academic Press, Inc. San Diego, CA. 701-713.
5. Rusinko, R., J.J. Yin, J. Yee, T. Saad, G.R. Mundy, and T.A. Guise. 1995. Parathyroid hormone (PTH) excess is associated with increased interleukin-6 (IL-6) and soluble IL-6 receptor (sIL-6r) production. J. Bone. Miner. Res. 10: S500(Abstr.).
6. Grey, A., M.A. Mitnick, S. Shapses, A. Ellison, C. Gundberg, and K. Insogna. 1996. Circulating levels of interleukin-6 and tumor necrosis factor-alpha are elevated in primary hyperparathyroidism and correlate with markers of bone resorption - a clinical research center study. J. Clin. Endocrinol. Metab. 81:3450-3454.
7. Roodman, G.D., N. Kurihara, Y. Ohsaki, A. Kukita, D. Hosking, A. Demulder, J.F. Smith, and F.R. Singer. 1992. Interleukin 6: a potential autocrine/paracrine factor in Paget's disease of bone. J. Clin. Invest. 89:46-52.
8. Klein, B., J. Wijdenes, X.-G. Zhang, M. Jourdan, J.-M. Boiron, J. Brochier, J. Liautard, M. Merlin, C. Clement, B. Morel-Fournier, et al. 1991. Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood. 78:1198-1204.
9. De Benedetti, F., M. Massa, P. Pignatti, S. Albani, D. Novick, and A. Martini. 1994. Serum soluble interleukin 6 (IL-6) receptor and IL-6/soluble IL-6 receptor complex in systemic juvenile rheumatoid arthritis. J. Clin. Invest. 93: 2114-2119.
10. Kotake, S., A. Sato, K.J. Kim, N. Takahashi, N. Udagawa, I. Nakamura, A. Yamaguchi, T. Suda, and T. Kashiwazaki. 1996. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J. Bone Miner. Res. 11:88-95.
11. Devlin, R.D., H.G. Bone, and G.D. Roodman. 1996. Interleukin-6: a potential mediator of the massive osteolysis in patients with Gorham-Stout disease. J. Clin. Endocrinol. Metab. 81:1893-1897.
12. Salvi, M., G. Girasole, M. Pedrazzoni, M. Passeri, N. Giuliani, R. Minelli, L.E. Braverman, and E. Roti. 1996. Increased serum concentrations of interleukin-6 (IL-6) and soluble IL-6 receptor in patients with Graves disease. J. Clin. Endocrinol. Metab. 81:2976-2979.
13. Lakatos, P., J. Foldes, C. Horvath, L. Kiss, A. Tatrai, I. Takacs, G. Tarjan, and P.H. Stern. 1997. Serum interleukin-6 and bone metabolism in patients with thyroid function disorders. J. Clin. Endocrinol. Metab. 82:78-81.
14. Yamamoto, T., K. Ozono, S. Kasayama, K. Yoh, K. Hiroshima, M. Takagi, S. Matsumoto, T. Michigami, K. Yamaoka, T. Kishimoto, and S. Okada. 1996. Increased IL-6 production by cells isolated from the fibrous bone dysplasia tissues in patients with McCune-Albright syndrome. J. Clin. Invest. 98:30-35.
15. Langub, M.C., N.J. Koszewski, H.V. Turner, M. Monier-Faugere, Z. Geng, and H.H. Malluche. 1996. Bone resorption and mRNA expression of IL-6 and IL-6 receptor in patients with renal osteodystrophy. Kidney Int. 50:515-520.
16. Girasole, G., R.L. Jilka, G. Passeri, S. Boswell, G. Boder, D.C. Williams, and S.C. Manolagas. 1992. 17β-estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in-vitro: a potential mechanism for the antiosteoporotic effect of estrogens. J. Clin. Invest. 89:883-891.
17. Pottratz, S., T. Bellido, H. Mocharla, D. Crabb, and S.C. Manolagas. 1994. 17β-estradiol inhibits expression of human interleukin-6 promoter-reporter constructs by a receptor-dependent mechanism. J. Clin. Invest. 93:944-950.
18. Ray, A., K.E. Prefontaine, and P. Ray. 1994. Down-modulation ot Interleukin-6 gene expression by 17β-estradiol in the absence of high affinity DNA binding by the estrogen receptor. J. Biol. Chem. 269:12940-12946.
19. Stein, B., and M.X. Yang. 1995. Repression of the Interleukin-6 Promoter by Estrogen Receptor Is Mediated by NF-κB and C/EBPβ. Mol. Cell. Biol. 15:4971-4979.
20. Bismar, H., I. Diel, R. Ziegler, and J. Pfeilschifter. 1995. Increased cytokine secretion by human bone marrow cells after menopause or discontinuation of estrogen replacement. J. Clin. Endocrinol. Metab. 80:3351-3355.
21. Passeri, G., G. Girasole, R.L. Jilka, and S.C. Manolagas. 1993. Increased interleukin-6 production by murine bone marrow and bone cells after estrogen withdrawal. Endocrinology. 133:822-828.
22. Miyaura, C., K. Kusano, T. Masuzawa, O. Chaki, Y. Onoe, M. Aoyagi, T. Sasaki, T. Tamura, Y. Koishihara, Y. Ohsugi, and T. Suda. 1995. Endogenous bone-resorbing factors in estrogen deficiency: cooperative effects of IL-1 and IL-6. J. Bone Miner. Res. 10:1365-1373.
23. Glasebrook, A.L., L.L. Short, H.W. Cole, M. Sato, and H.U. Bryant. 1995. Regulation of serum IL-6 by raloxifene in an ovx rat model. Bone. 16: 99S(Abstr.).
24. Zuckerman, S.H., N. Bryan-Poole, G.F. Evans, L. Short, and A.L. Glasebrook. 1995. In vivo modulation of murine serum tumour necrosis factor and interleukin-6 levels during endotoxemia by oestrogen agonists and antagonists. Immunology. 86:18-24.
25. McKane, W.R., S. Khosla, J.M. Peterson, K. Egan, and B.L. Riggs. 1994. Circulating levels of cytokines that modulate bone resorption: effects of age and menopause in women. J. Bone Miner. Res. 9:1313-1318.
26. Kassem, M., S. Khosla, T.C. Spelsberg, and L. Riggs. 1996. Cytokine production in the bone marrow microenvironment: failure to demonstrate estrogen regulation in early postmenopausal women. J. Clin. Endocrinol. Metab. 81:513-518.
27. Poli, V., R. Balena, E. Fattori, A. Markatos, A. Yamamoto, H. Tanaka, G. Ciliberto, G.A. Rodan, and F. Costantini. 1994. Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion. EMBO J. 13:1189-1196.
28. Stahl, N., and G.D. Yancopoulos. 1993. The alphas, betas, and kinases of cytokine receptor complexes. Cell. 74:1-4.
29. Kishimoto, T., T. Taga, and S. Akira. 1994. Cytokine signal transduction. Cell. 76:253-262.
30. Zhong, Z., Z. Wen, and J.E.J. Darnell. 1994. Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science (Wash. DC). 264:95-98.
31. Ihle, J.N. 1996. STATs: signal transducers and activators of transcription. Cell. 84:331-334.
32. Girasole, G., G. Passeri, R.L. Jilka, and S.C. Manolagas. 1994. Interleukin-11: a new cytokine critical for osteoclast development. J. Clin. Invest. 93: 1516-1524.
33. De La Mata, J., H.L. Uy, T.A. Guise, B. Story, B.F. Boyce, G.R. Mundy, and G.D. Roodman. 1995. Interleukin-6 enhances hypercalcemia and bone resorption mediated by parathyroid hormone-related protein in vivo. J. Clin. Invest. 95:2846-2852.
34. Bellido, T., N. Stahl, T.J. Farruggella, V. Borba, G.D. Yancopoulos, and S. Manolagas. 1996. Detection of receptors for interleukin-6, interleukin-11, leukemia inhibitory factor, oncostatin M, and ciliary neurotrophic factor in bone marrow stromal/osteoblastic cells. J. Clin. Invest. 97:431-437.
35. Tamura, T., N. Udagawa, N. Takahashi, C. Miyaura, S. Tanaka, Y. Yamada, Y. Koishihara, Y. Ohsugi, K. Kumaki, T. Taga, et al. 1993. Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. Proc. Natl. Acad. Sci. USA. 90:11924-11928.
36. Sudo, H., H.A. Kodama, Y. Amagai, S. Yamamoto, and S. Kasai. 1983. In vitro differentiation and calcification in a new clonal osteogenic cell line derived from newborn mouse calvaria. J. Cell Biol. 96:191-198.
37. Heremans, H., A. Billiau, J.J. Cassiman, J.C. Mulier, and P. Desomer. 1978. In vitro cultivation of human tissues II. Morphology and virological characteristics of three cell lines. Oncology (Basel). 35:246-252.
38. Fogh, J., W.C. Wright, and J.D. Loveless. 1977. Absence of HeLa cell contamination in 169 cell lines derived from human tumors. J. Natl. Cancer Inst. 58:209-214.
39. Mocharla, H., A.W. Butch, A.A. Pappas, J.T. Flick, R.S. Weinstein, P. DeTogni, R.L. Jilka, P.K. Roberson, A.M. Parfitt, and S.C. Manolagas. 1997. Quantification of vitamin D receptor mRNA by competitive polymerase chain reaction in PBMC: lack of correspondence with common allelic variants. J. Bone Miner. Res. 12:726-733.
40. Saito, M., K. Yoshida, M. Hibi, T. Taga, and T. Kishimoto. 1992. Molecular cloning of a murine IL-6 receptor-associated signal transducer, gp130, and its regulated expression in vivo. J. Immunol. 148:4066-4071.
41. Stahl, N., S. Davis, V. Wong, T. Taga, T. Kishimoto, N.Y. Ip, and G.D. Yancopoulos. 1993. Cross-linking identifies leukemia inhibitory factor-binding protein as a ciliary neurotrophic factor receptor component. J. Biol. Chem. 268: 7628-7631.
42. Sakagami, Y., G. Girasole, X. Yu, H.S. Boswell, and S.C. Manolagas. 1993. Stimulation of interleukin-6 production by either calcitonin gene-related peptide or parathyroid hormone in two phenotypically distinct bone marrow-derived murine stromal cell lines. J. Bone Miner. Res. 8:811-816.
43. Owen, T.A., M.S. Aronow, L.M. Barone, B. Bettencourt, G.S. Stein, and J.B. Lian. 1991. Pleiotropic effects of vitamin D on osteoblast gene expression are related to the proliferative and differentiated state of the bone cell phenotype: dependency upon basal levels of gene expression, duration of exposure, and bone matrix competency in normal rat osteoblast cultures. Endocrinology. 128:1496-1504.
44. Suda, T., N. Takahashi, and T.J. Martin. 1995. Modulation of osteoclast differentiation: update 1995. Endocr. Rev. 4:266-270.
45. Girasole, G., M. Pedrazzoni, N. Giuliani, G. Passeri, and M. Passeri. 1995. Increased serum soluble interleukin-6 receptors levels are induced by ovariectomy, prevented by estrogen replacement and reversed by alendronate administration. J. Bone Miner. Res. 10:S160(Abstr.).
46. Chen, J.T., N. Maruo, T. Kato, E. Hasumi, E. Ogata, M. Shiraki, and I. Morita. 1996. Serum level of soluble interleukin-6 receptor, not interleukin-6, is correlated with bone resorption markers and lumbar bone mineral density after menopause. J. Bone Miner. Res. 10:S347(Abstr.).
47. Feyen, J.H.M., P. Elford, R.E. Dipadova, and U. Trechsel. 1989. Interleukin-6 is produced by bone and modulated by parathyroid hormone. J. Bone Miner. Res. 4:633-638.
48. Lowik, C.W.G.M., G. van der Pluijm, H. Bloys, K. Hoekman, O.L.M. Bijvoet, L.A. Aarden, and S.E. Papapoulos. 1989. Parathyroid hormone (PTH) and PTH-like protein (PLP) stimulate interleukin-6 production by osteogenic cells: a possible role of interleukin-6 in osteoclastogenesis. Biochem. Biophys. Res. Commun. 162:1546-1552.
49. Greenfield, E.M., S.M. Shaw, S.A. Gornik, and M.A. Banks. 1995. Adenyl cyclase and interleukin 6 are downstream effectors of parathyroid hormone resulting in stimulation of bone resorption. J. Clin. Invest. 96:1238-1244.
50. Cosman, F., V. Shen, F. Xie, M. Seibel, A. Ratcliffe, and R. Lindsay. 1993. Estrogen protection against bone resorbing effects of parathyroid hormone infusion. Ann. Intern. Med. 118:337-343.
51. Bellido, T., G. Girasole, G. Passeri, R.L. Jilka, and S.C. Manolagas. 1994. gp130 mRNA is increased by PTH and cytokines and decreased by sex steroids in stromal/osteoblastic cells. J. Bone Miner. Res. 9:S123(Abstr.).
52. Romas, E., N. Udagawa, H. Zhou, T. Tamura, M. Saito, T. Taga, D.J. Hilton, T. Suda, K.W. Ng, and T.J. Martin. 1996. The role of gp130-mediated signals in osteoclast development: regulation of interleukin 11 production by osteoblasts and distribution of its receptor in bone marrow cultures. J. Exp. Med. 183:2581-2591.
53. Schoester, M., P.C. Heinrch, and L. Graeve. 1994. Regulation of interleukin-6 receptor expression by interleukin-6 in human monocytes - a re-examination. FEBS Lett. 343:131-134.
54. Snyers, L., and J. Content. 1992. Enhancement of IL-6 receptor β chain (gp130) expression by IL-6, IL-1, and TNF in human epithelial cells. Biochem. Biophys. Res. Commun. 185:902-908.
55. Schooltink, H., H. Schmitz-Van de Leur, P.C. Heinrich, and S. Rose-John. 1992. Up-regulation of the interleukin-6-signal transducing protein (gp130) by interleukin-6 and dexamethasone in HepG2 cells. FEBS Lett. 297: 263-265.
56. Sidell, N., T. Taga, T. Hirano, T. Kishimoto, and A. Saxon. 1991. Retinoic acid-induced growth inhibition of a human myeloma cell line via down-regulation of IL-6 receptors. J. Immunol. 146:3809-3814.
57. Lin, S.-C., C.A. O'Brien, and S.C. Manolagas. 1996. Sex steroids decrease and glucocorticoids increase the levels of gp130 protein in bone marrow-derived stromal cells: correlation with altered IL-6 induced DNA-binding activity of Stat1 and Stat3 complexes. J. Bone Miner. Res. 11:S161(Abstr.)
58. Murakami-Mori, K., T. Taga, T. Kishimoto, and S. Nakamura. 1995. AIDS-associated Kaposi's sarcoma (KS) cells express oncostatin M (OM)-specific receptor but not leukemia inhibitory factor/OM receptor or Interleukin-6 receptor. J. Clin. Invest. 96:1319-1327.
59. Metcalf, D., and D.P. Gearing. 1989. Fatal syndrome in mice engrafted with cells producing high levels of the leukemia inhibitory factor. Proc. Natl. Acad. Sci. USA. 86:5948-5952.
60. Takahashi, K., R.L. Jilka, and S.C. Manolagas. 1996. Estrogens alters the responsiveness of osteoblast progenitors to leukemia inhibitory factor (LIF). J. Bone Miner. Res. 11:S129(Abstr.).
61. Taguchi, Y., T. Yamate, H. Mocharla, S.-C. Lin, A. Vertino, P. DeTogni, E. Abe, and S.C. Manolagas. 1996. Interleukin-6 induces osteoblast differentiation in uncommitted embryonic fibroblasts (EF). J. Bone Miner. Res. 11:S101(Abstr.).
62. Ware, C.B., M.C. Horowitz, B.R. Renshaw, J.S. Hunt, D. Liggitt, S.A. Koblar, B.C. Gliniak, H.J. McKenna, T. Papayannopoulou, B. Thoma, et al. 1995. Targeted disruption of the low-affinity leukemia inhibitory factor receptor gene causes placental, skeletal, neural, and metabolic defects and results in perinatal death. Development (Cambridge). 121:1283-1299.
63. Malik, N., H.S. Haugen, B. Modrell, M. Shoyab, and C.H. Clegg. 1995. Developmental abnormalities in mice transgenic for bovine oncostatin M. Mol. Cell. Biol. 15:2349-2358.
64. Bellido, T., V.Z.C. Borba, P.K. Roberson, and S.C. Manolagas. 1997. Activation of the JAK/STAT signal transduction pathway by IL-6 type cytokines promotes osteoblasl differentiation. Endocrinology. 138:3666-3676.